# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work.
Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to...
BMO Capital analyst Evan David Seigerman reiterates Pfizer (NYSE:PFE) with a Outperform and raises the price target from $33...
Wednesday saw a mixed performance in major U.S. indices. The Dow Jones Industrial Average closed the day with a 0.2% increase a...